Part:BBa_K3335003

We used it to express iRGD-Lamp2b and siRNA targeted at KRAS

We used it to express iRGD-Lamp2b and siRNA targeted at KRAS Lung cancer is the major cause of cancer-related deaths globally. Mutant KRAS is a feature of 15%–50% of lung cancer cases[1]. Unfortunately, although much effort has been spent on searching for small molecule inhibitors of KRAS, KRAS gene has proven extraordinarily difficult to target by current pharmacological agents.

This year we developed an alternative strategy to silence the so-called untargetable and undruggable KRAS gene by employing exosome-mediated siRNA delivery.At the same time, we used iRGDLamp2b to achieve exosome targeting. Particularly, we reprogrammed cells to simultaneously express KRAS siRNA and Lamp2b. Lamp2b is an exosomal membrane protein, in fusion with a tumor-penetrating internalizing RGD (iRGD) peptide (CRGDKGPDC), and then produce the tumor-targeting exosomes as KRAS siRNA delivery system.[1]

With this system, we can target tumor cells and deliver siRNA.

[1]Yu Zhou et al.,Tumor-specific delivery of KRAS siRNA with iRGD-exosomes efficiently inhibits tumor growth. ExRNA,2019.

Usage and Biology

Sequence and Features

Assembly Compatibility:

• 10
  COMPATIBLE WITH RFC[10]
• 12
  COMPATIBLE WITH RFC[12]
• 21
  COMPATIBLE WITH RFC[21]
• 23
  COMPATIBLE WITH RFC[23]
• 25
  INCOMPATIBLE WITH RFC[25]

  Illegal NgoMIV site found at 1277
  
• 1000
  COMPATIBLE WITH RFC[1000]

KRAS siRNA overexpressed in HEK293T cell and exosome

First, we detected the correct expression of KRAS siRNA through RT-QPCR to ensure that sufficient targeted siRNA could be produced in cell. CMV-iRGD-siRK is this part. CMV-iRGD-siR^P+C+K is a Composite part.